SCHEMBL17218267

SCHEMBL17218267

N#Cc1ccc([C]=NOCc2cccc(Cl)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 2/20 0.51
▸ MRGPRX4 Q96LA9 2/20 0.47
▸ CYP3A4 P08684 2/20 0.46
▸ IDO1 P14902 2/20 0.46
▸ AGXT P21549 2/20 0.46
▸ MAOB P27338 5/20 0.43
▸ NR3C1 P04150 1/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RXRA P19793 1/20 0.40
▸ RXRB P28702 1/20 0.40
▸ RXRG P48443 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ NR4A2 P43354 1/20 0.39
▸ MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17218265 1.00 GRM5 (0.51) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17219555 0.90 MRGPRX4 (0.52) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17219554 0.90 MRGPRX4 (0.52) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17217330 0.89 CYP3A4 (0.50) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17217332 0.89 CYP3A4 (0.50) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17216089 0.89 MRGPRX4 (0.54) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17216088 0.89 MRGPRX4 (0.54) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17216854 0.89 NPC1 (0.45) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17216855 0.89 NPC1 (0.45) GRM5MRGPRX4CYP3A4IDO1AGXT
SCHEMBL17218965 0.89 MRGPRX4 (0.54) GRM5MRGPRX4CYP3A4IDO1AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 GRM5 1017/4885MRGPRX4 1822/4885CYP3A4 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback